The Science and Manufacturing Behind Botulinum Neurotoxin Type A-ABO in Clinical Use

Aesthetic Surgery Journal

Volumn 29, Issue 6 SUPPL., 2009, Pages

  Wortzman, Mitchell S ^a   Pickett, Andy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUROTOXIN; PLACEBO; PROTEINASE;

ARTICLE; BLEPHAROSPASM; CERVICAL DYSTONIA; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; COLUMN CHROMATOGRAPHY; DRUG DIFFUSION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STABILITY; DRUG UPTAKE; ENZYME ACTIVITY; FLACCID PARALYSIS; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PTOSIS; RHINOPHARYNGITIS; SPASTICITY; STOMACH; STRABISMUS; TORTICOLLIS; TRANSCYTOSIS;

BOTULINUM TOXIN TYPE A; CHEMISTRY, PHARMACEUTICAL; COSMETIC TECHNIQUES; HUMANS; NEUROTOXINS;

EID: 71549126807     PISSN: 1090820X     EISSN: 1527330X     Source Type: Journal    
DOI: 10.1016/j.asj.2009.09.014     Document Type: Article

References (75)

1. American Society for Aesthetic Plastic Surgery Web site. Cosmetic surgery National Data Bank statistics, 2008. (Accessed 8/29/09, at http://www.surgery.org/sites/default/files/2008stats.pdf)
2. Hasegawa K., Watanabe T., Suzuki T., et al. A novel subunit structure of Clostridium botulinum serotype D toxin complex with three extended arms. J Biol Chem 282 (2007) 24777-24783
3. Wenzel R.G. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 61 22 suppl 6 (2004) S5-S10
4. Klein A.W. Complications with the use of botulinum toxin. Dermatol Clin 22 (2004) 197-205
5. Lamanna C. The most poisonous poison. Science 130 (1959) 763-772
6. Chertow D.S., Tan E.T., Maslanka S.E., et al. Botulism in 4 adults following aesthetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 296 (2006) 2476-2479
7. Scott A.B., and Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3 (1988) 333-335
8. Herrero B.A., Ecklung A.E., Streett C.S., Ford D.F., and King J.K. Experimental botulism in monkeys-a clinical pathological study. Exp Mol Pathol 6 (1967) 84-95
9. Sesardic D., and Das R.G. Botulinum toxin: applying the 3Rs to product potencyy testing. (Accessed 6/22/09, at http://www.nc3rs.org.uk/news.asp?id=1023)
10. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 (2001) 1059-1070
11. Smith T.J., Hill K.K., Foley B.T., et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters relocated within plasmids. PLos One 12 (2007) e1271
12. Ward A.B., and Barnes M. Introduction. In: Ward A.B., and Barnes M. (Eds). Clinical uses of botulinum toxins. 1st ed. (2007), Cambridge University Press, New York
13. Scott A.B. Development of botulinum toxin therapy. Dermatol Clin 22 (2004) 131-133
14. Scott A.B., Rosenbaum A., and Collins C.C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12 (1973) 924-927
15. Ting P.T., and Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med 4 (2004) 258-261
16. Carruthers A., Kiene K., and Carruthers J. Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34 5 pt 1 (1996) 788-797
17. Carruthers A., and Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol Surg 24 (1998) 1168-1170
18. Matarasso A., Matarasso S.L., Brandt F.S., and Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 103 (1999) 645-652
19. Keller J.E. Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139 (2006) 629-637
20. Botulinum toxin. AHFS Drug Information (2008), American Society of Health-System Pharmacists, Bethesda, MD
21. Ravichandran E., Gong Y., Al Saleem F.H., Ancharski D.M., Joshi S.G., and Simpson L.L. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther 318 (2006) 1343-1351
22. Crowner B.E., Brunstrom J.E., and Racette B.A. Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 30 (2007) 310-313
23. Bakheit A.M., Ward C.D., and McLellan D.L. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 62 (1997) 198
24. Tugnoli V., Eleopra R., Quatrale R., Capone J.G., Sensi M., and Gastaldo E. Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis. Br J Dermatol 147 (2002) 808-809
25. Cobb D.B., Watson W.A., and Fernandez M.C. Botulism-like syndrome after injections of botulinum toxin. Vet Hum Toxicol 42 (2000) 163
26. Partikian A., and Mitchell W.G. Iatrogenic botulism in a child with spastic quadriparesis. J Child Neurol 22 (2007) 1235-1237
27. Misuse of super-strength Botox paralyzes victims. (Accessed 5/28/09, at http://www.news-medical.net/news/21075.aspx)
28. US Food and Drug Administration Web site. Drug safety updates for healthcare professionals: botulinum toxin. (Accessed 6/22/09, at http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/UCM143989.pdf)
29. US Food and Drug Administration Web site. FDA law enforcers crack down on illegal botox scammers. (Accessed 6/22/09, at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm048377.htm)
30. Pickett A, Mewies M. Counterfeit botulinum toxins-a serious risk to patient safety. Presented in poster form at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Baveno, Italy, June 12-15, 2008.
31. Pickett A., and Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol 61 (2009) 149-150
32. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon 54 (2009) 683-689
33. Tang-Liu D.D., Aoki K.R., Dolly J.O., et al. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution. Toxicon 42 (2003) 461-469
34. Antonucci F., Rossi C., Gianfranceschi L., Rossetto O., and Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci 28 (2008) 3689-3696
35. Talan J. Study finds botulinum toxin spreads to CNS tissue in mice. Neurology Today 8 (2008) 22-23
36. Caleo M., Antonucci F., Restani L., and Mazzocchio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism?. J Neurochem 109 (2009) 15-24
37. Abbruzzese G., and Berardelli A. Neurophysiological effects of botulinum toxin type A. Neurotox Res 9 (2006) 109-114
38. Ce P. Central effects of botulinum toxin: study of brainstem auditory evoked potentials. Eur J Neurol 7 (2000) 747
39. Boroojerdi B., Cohen L.G., and Hallett M. Effects of botulinum toxin on motor system excitability in patients with writer's cramp. Neurology 61 (2003) 1546-1550
40. Gilio F., Currà A., Lorenzano C., Modugno N., Manfredi M., and Berardelli A. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia. Ann Neurol 48 (2000) 20-26
41. Cliff S.H. Migration characteristics of botulinum neurotoxins. Cosmet Dermatol 20 suppl 3 (2007) 32-35
42. Cliff S.H., Judodihardjo H., and Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 7 (2008) 50-54
43. de Almeida A.T., and De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther 9 suppl 1 (2007) 17-22
44. Eisele K.H., and Taylor H.V. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. Presented in poster form at Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins, Baveno, Italy, June 12-15, 2008 (P164 published as an abstract in. Toxicon 51 suppl 1 (2008) 10
45. Friday D., Bigalke H., and Frevert J. In vitro stability of botulinum toxin complex preparations at physiological pH and temperature. Arch Pharmacol 365 suppl 2 (2002) R20
46. US Food and Drug Administration Web site. FDA requires boxed warning for all botulinum toxin products. (Accessed 6/22/09, at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149574.htm)
47. Moy R., Maas C., Monheit G., Huber M., and Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 11 (2009) 77-83
48. Monheit G., Carruthers A., Brandt F., and Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 33 1 spec no. (2007) S51-S59
49. Dressler D., and Hallett M. Immunological aspects of Botox, Dysport, and Myobloc/NeuroBloc. Eur J Neurol 13 suppl 1 (2006) 11-15
50. Aoki K.R. Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 6 suppl 4 (1996) S3-S10
51. Jost W.H., Blümel J., and Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 67 (2007) 669-683
52. Medicis press release. FDA approves Dysport for therapeutic and aesthetic uses. (Accessed 6/2/09, at http://www.irconnect.com/mrx/pages/news_releases.html?d=164270)
53. Panjwani N., O'Keefe R., and Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J 1 (2008) 153-166
54. Bonventre P.F., and Kempe L.L. Physiology of toxin production by Clostridium botulinum types A and B. III. Effect of pH and temperature during incubation on growth, autolysis, and toxin production. Appl Microbiol 7 (1959) 374-377
55. Poulain B., Popoff M.R., and Molgó J. How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action. The Botulinum J 1 (2008) 14-87
56. Karsai S., and Raulin C. Do different formulations of botulinum toxin type A really have different migration characteristics?. J Cosmet Dermatol 7 (2008) 230
57. Dong M., Liu H., Tepp W.H., Johnson E.A., Janz R., and Chapman E.R. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons. Mol Biol Cell 19 (2008) 5226-5237
58. Montana V., Liu W., Mohideen U., and Parpura V. Single molecule measurements of mechanical interactions within ternary SNARE complexes and dynamics of their disassembly: SNAP25 vs. SNAP23. J Physiol 587 pt 9 (2009) 1943-1960
59. Cheng L.W., Onisco B., Johnson E.A., et al. Effects of purification on the bioavailability of botulinum neurotoxin type A. Toxicology 249 (2008) 123-129
60. Fischer A., Mushrush D.J., Lacy D.B., and Montal M. Botulinum neurotoxin devoid of receptor binding domain translocates active protease. PLoS Pathog 4 (2008) e1000245. Epub 2008 Dec 19.
61. Binz T., and Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem 109 (2009) 1584-1595
62. Silvaggi N.R., Wilson D., Tzipori S., and Allen K.N. Catalytic Features of the Botulinum Neurotoxin A Light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 47 (2008) 5736-5745
63. Hines H.B., Lebeda F., Hale M., and Brueggemann E.E. Characterization of botulinum progenitor toxins by mass spectrometry. Appl Environ Microbiol 71 (2005) 4478-4486
64. Inoue K., Fujinaga Y., Watanabe T., et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 64 (1996) 1589-1594
65. Hines H.B., Kim A.D., Stafford R.G., et al. Use of a recombinant fluorescent substrate with cleavage sites for all botulinum neurotoxins in high-throughput screening of natural product extracts for inhibitors of serotypes A, B, and E. Appl Environ Microbiol 74 (2008) 653-659
66. Sharma S.K., and Singh B.R. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins. Biochemistry 43 (2004) 4791-4798
67. Brandau D.T., Joshi S.B., Smalter A.M., Kim S., Steadman B., and Middaugh C.R. Stability of the Clostridium botulinum type A neurotoxin complex: an empirical phase diagram based approach. Mol Pharm 4 (2007) 571-582
68. Koussoulakos S. Botulinum neurotoxin: the ugly duckling. Eur Neurol 61 (2009) 331-342
69. Jankovic J., Albanese A., and Hallett M. Unique properties of botulinum toxins. Toxicon 54 (2009) 675
70. Reuters Web site. Ipsen: FDA's first-cycle review of Reloxin extended. (Accessed 6/22/09, at http://www.reuters.com/article/pressRelease/idUS197796+07-Jan-2009+BW20090107)
71. Klein A.W., Carruthers A., Fagien S., and Lowe N.J. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg 121 (2008) 413e-422e
72. Straughan D.W. Progress in applying the three Rs to the potency testing of botulinum toxin type A. Altern Lab Anim 34 (2006) 305-313
73. Dysport [package insert] (2009), Ipsen Biopharm, Wrexham, UK
74. Botox Cosmetic [package insert] (2009), Allergan, Irvine, CA
75. Jankovic J., Vuong K.D., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188